Oncology Times

Skip Navigation LinksHome > Collections > Lymphoma

Lymphoma

Creator:   Editor
Created:   8/7/2010
Contains:  35 items
Lymphoma articles published in 2010

Show
Previous of 1 Next

Stem Cell Transplantation for HIV-Associated Lymphoma

Free Access
PDF
+ Favorites
Request Permissions

FDA Approves Bendeka (Bendamustine Hydrochloride) Injection for CLL and NHL

Free Access
PDF
+ Favorites
Request Permissions

Protein Associated with Myeloma & DLBCL also Found to Play Role in CTCL

Free Access
PDF
+ Favorites
Request Permissions

Hodgkin Lymphoma Survivors Face Long-term Elevated Risk of Cardiovascular Disease

Free Access
PDF
+ Favorites
Request Permissions

Mantle Cell Lymphoma: Follow-Up Confirms Ibrutinib's Benefits in Relapsed/Refractory Disease

Free Access
PDF
+ Favorites
Request Permissions

The Lymphoma-Melanoma Connection

Free Access
PDF
+ Favorites
Request Permissions

CTCL: Early Results Promising for Topical Gel

Free Access
PDF
+ Favorites
Request Permissions

FDA Approves Adcetris for Another HL Indication

Free Access
PDF
+ Favorites
Request Permissions

Next-Gen Genomics Hit Lymphoma Diagnosis, Therapy

Free Access
PDF
+ Favorites
Request Permissions

WHO Lymphoma Classification Update in Progress, but Is It ‘Too Complicated’?

Free Access
PDF
+ Favorites
Request Permissions

NHL: Inotuzumab Ozogamicin Shows Activity Both Alone & Combined with Rituximab

Free Access
PDF
+ Favorites
Request Permissions

ASH ANNUAL MEETING: Brentuximab Shows High Response Rates in Relapsed Refractory Lymphomas

Free Access
PDF
+ Favorites
Request Permissions

ASH Plenary Study: For Follicular Lymphoma, Use of Rituximab in Asymptomatic Patients Prolongs Time to Initial Treatment—But Not Survival

Free Access
PDF
+ Favorites
Request Permissions

BAFF Mutation Also Found in NHL

Free Access
PDF
+ Favorites
Request Permissions

Immunoconjugates: Rapidly Changing & Promising Field

Free Access
PDF
+ Favorites
Request Permissions

Follicular Lymphoma: Time to Reevaluate ‘Watch and Wait’?

Free Access
PDF
+ Favorites
Request Permissions

Documented: Chronic Health Conditions Remain a Problem for Hematopoietic Cell Transplant Patients

Free Access
PDF
+ Favorites
Request Permissions

NCCN Publishes Guidelines for Cancer Patients

Free Access
PDF
+ Favorites
Request Permissions

Survey: Most Adults in US Unaware of Scope of Lymphoma

Free Access
PDF
+ Favorites
Request Permissions

‘Henry Kaplan and the Story of Hodgkin's Disease’ by Charlotte DeCroes Jacobs'

Free Access
PDF
+ Favorites
Request Permissions

Profiles in Oncology Social Media: Anas Younes, MD — @DrAnasYounes (#4 in a Continuing Series)

Free Access
PDF
+ Favorites
Request Permissions

Post-Transplant Lymphoproliferative Disease: Update on Current Treatment Options

Free Access
PDF
+ Favorites
Request Permissions

High Occurrence of Thrombosis Found in Lymphoma Patients

Free Access
PDF
+ Favorites
Request Permissions

Untreated Indolent B-Cell NHL: Biologics Produce Complete Responses

Free Access
PDF
+ Favorites
Request Permissions

Expanding the Scope of Bendamustine

Free Access
PDF
+ Favorites
Request Permissions

Diffuse Large B-Cell Lymphoma: Bendamustine-Rituximab Effective as Second-Line Therapy

Free Access
PDF
+ Favorites
Request Permissions

From ASCO Annual Meeting: HIV-Lymphoma: Little Efficacy Found for Liposomal Anthracycline

Free Access
PDF
+ Favorites
Request Permissions

From ASCO Annual Meeting: Gene Variants Predict Anthracycline Cardiotoxicity in Young Patients

Free Access
PDF
+ Favorites
Request Permissions

For Men Considered Sterile after BMT for Hematological Malignancies, New Technique Makes It Possible to Father Children

Free Access
PDF
+ Favorites
Request Permissions

Potential New Standard for First-Line Treatment of Lymphomas: Bendamustine + Rituximab

Free Access
PDF
+ Favorites
Request Permissions

Program 2, Sunday Dec. 6

Creator: Peter Goodwin
Duration: 19:00
Oncology Times 

George Canellos, What’s hot from the ASH Plenary Session.

Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner drug for bortezomib in multiple myeloma; Commentary Dr. Canellos and Jesus San-Miguel, also of Salamanca, and Richard Van Etten of Tufts University.

Steven Devine of Ohio State University on T-cell depletion to avoid GVHD in AML; commentary from Dr. Canellos and Armand Keating of the University of Toronto.

Download (3.91 MB)
+ Favorites

Program 3, Monday Dec 7

Creator: Peter Goodwin
Duration: 23:20
Oncology Times 

George Canellos on aggressive chemotherapy's failure to benefit patients with high-risk B-cell lymphoma.

Massimo Martelli of University of Perugia on infused donor T-regulatory cells to prevent graft-vs-host-disease in patients with leukemia & lymphoma; comments from Armand Keating of the University of Toronto.

Mathias Rummel of University Hospital in Germany on using bendamustine rather than CHOP combined with rituximab for treating indolent lymphomas—front-line. Commenting: Dr. Canellos and Richard Van Etten of Tufts University.

Eduardo Rego of the University of Sao Paolo on his networking between North and South America to improve treatment of APL in developing countries. Adding their thoughts: Dr. Canellos and Richard Larson of the University of Chicago. OT Interviewers: Peter Goodwin and Sarah Maxwell.

Download (4.88 MB)
+ Favorites

Program 4, Day 4, Monday Dec 8

Creator: Peter Goodwin
Duration: 22:07
Oncology Times 

Prof Giuseppe Saglio of the University of Turin and San Luigi Gonzaga Hospital in Italy on nilotinib as a new standard of care for chronic myeloid leukaemia. ASH President Nancy Berliner of Brigham & Women's Hospital adds her thoughts.

Jorge Cortes of M. D. Anderson Cancer Center on three different ASH papers by his group looking at alternatives to standard imatinib in CML. Jane Apperley of Hammersmith Hospital and Imperial College London, reflects on these, and discusses strategies for dealing with imatinib resistance.

OT Broadcast News Scientific Editor George Canellos of Dana-Farber Cancer Institute on what some were jokingly calling a re-run of World War II that took place in the Non-Hodgkin’s Lymphoma session: R-CHOP 14 vs R-CHOP 21 in elderly patients with diffuse large B-cell lymphoma.

Andrzej Jakubowiak of the University of Michigan discusses a 4-drug regimen to treat newly diagnosed multiple myeloma....Ruben Niesvizky of Weill Cornell Medical College in New York City on the novel proteasome inhibitor carfilzomib, used in combination with lenalidomide and dexamethasone to treat relapsed or refractory multiple myeloma. OT interviewers: Peter Goodwin and Sarah Maxwell.

Download (4.89 MB)
+ Favorites

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA...

Duration: 8:12
Oncology Times 

Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with patients who did not.

Download (1.93 MB)
+ Favorites
Show
Previous of 1 Next
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.